These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 6221548)

  • 1. Effects of selective thromboxane synthetase inhibitor and indomethacin on prostacyclin and thromboxane A2 from ischemic canine heart.
    Ogawa K; Sakai K; Ito T; Watanabe J; Satake T
    Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():371-6. PubMed ID: 6221548
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of a selective inhibitor of thromboxane synthetase (OKY-1581) in humans.
    Ito T; Ogawa K; Sakai K; Watanabe J; Satake T; Kayama N; Hiraku S; Naito J
    Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():245-51. PubMed ID: 6221531
    [No Abstract]   [Full Text] [Related]  

  • 3. Stimulation of vessel wall prostacyclin by selective thromboxane synthetase inhibitor OKY 1581.
    Mehta J; Mehta P; Ostrowski N
    Prostaglandins Leukot Med; 1983 Sep; 12(1):49-52. PubMed ID: 6356153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of intravenous infusion of OKY-1581 (sodium-(E)-3-[4-(3-pyridylmethyl)phenyl] -2-methylacrylate) on circulatory thromboxane A2 and prostacyclin levels in anaesthetized baboon.
    Roy AC; Adaikan PG; Karim SM
    Prostaglandins Med; 1981 Sep; 7(3):253-9. PubMed ID: 7029585
    [No Abstract]   [Full Text] [Related]  

  • 5. Intravenous infusion of a selective inhibitor of thromboxane A2 synthetase in man: influence on thromboxane B2 and 6-keto-prostaglandin F1 alpha levels and platelet aggregation.
    Yui Y; Hattori R; Takatsu Y; Nakajima H; Wakabayashi A; Kawai C; Kayama N; Hiraku S; Inagawa T; Tsubojima M
    Circulation; 1984 Oct; 70(4):599-605. PubMed ID: 6434196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostacyclin and thromboxane levels during cardiac ischemia in dogs.
    Prosdocimi M; Tessari F; Finesso M; Gorio A; Dejana E; Languino LR; Del Maschio A; de Gaetano G
    Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():93-6. PubMed ID: 3159235
    [No Abstract]   [Full Text] [Related]  

  • 7. [The effect of thromboxane (Tx)A2 synthetase inhibitor (OKY-046) on airway hyperresponsiveness induced by ozone exposure in beagles].
    Kobayashi H; Adachi M; Satoh H; Okada Y; Takahashi T; Yamaguchi H
    Arerugi; 1985 Jul; 34(7):469-73. PubMed ID: 4062570
    [No Abstract]   [Full Text] [Related]  

  • 8. Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis.
    Aiken JW; Shebuski RJ; Miller OV; Gorman RR
    J Pharmacol Exp Ther; 1981 Nov; 219(2):299-308. PubMed ID: 6270303
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of thromboxane synthetase inhibitors on cyclical reduction of coronary blood flow in dogs.
    Uchida Y; Murao S
    Jpn Heart J; 1981 Nov; 22(6):971-5. PubMed ID: 7040725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective effects of selective inhibitor of thromboxane synthetase (OKY-046) and thromboxane antagonist (ONO-3708) on ischemia-induced mitochondrial dysfunction in canine heart.
    Ito T; Ito Y; Torii T; Hieda N; Toki Y; Miyazaki Y; Hashimoto H; Ogawa K; Satake T
    Adv Prostaglandin Thromboxane Leukot Res; 1987; 17A():392-6. PubMed ID: 2959085
    [No Abstract]   [Full Text] [Related]  

  • 11. Roles of endogenous prostacyclin and thromboxane A2 in the ischemic canine heart.
    Sakai K; Ito K; Ogawa K
    J Cardiovasc Pharmacol; 1982; 4(1):129-35. PubMed ID: 6176788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Experimental investigation on the pathogenesis of endotoxin shock--the change of plasma serotonin, histamine, thromboxane B2 and 6-keto PGF1 alpha levels and modulation by indomethacin (author's transl)].
    Ishihara Y; Kitamura S; Kosaka K
    Nihon Kyobu Shikkan Gakkai Zasshi; 1982 Feb; 20(2):207-13. PubMed ID: 6896537
    [No Abstract]   [Full Text] [Related]  

  • 13. Pulmonary vascular responses to thromboxane A2 as unmasked by OKY-1581. A novel inhibitor of thromboxane synthesis.
    Kadowitz PJ; Nandiwada PA; Spannhake EW; Rosenson RS; McNamara DB; Hyman AL
    Chest; 1983 May; 83(5 Suppl):72S-74S. PubMed ID: 6404609
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardioprotective actions of a selective thromboxane synthetase inhibitor in acute myocardial ischemia.
    Burke SE; Lefer DJ; Lefer AM
    Arch Int Pharmacodyn Ther; 1983 Sep; 265(1):76-84. PubMed ID: 6686001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of selective thromboxane synthetase inhibitor OKY-046 on plasma prostaglandins in patients with coronary artery disease during exercise.
    Shikano M; Ogawa K; Ito T; Chen LS; Ito Y; Imaizumi M; Uno T; Tsutsumi S; Satake T
    Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():375-7. PubMed ID: 3159226
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacological studies on OKY-1581: a selective thromboxane synthetase inhibitor.
    Hiraku S; Wakitani K; Katsube N; Kawasaki A; Tsuboshima M; Naito J; Ujiie A; Komatsu H; Iizuka K
    Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():241-4. PubMed ID: 6221530
    [No Abstract]   [Full Text] [Related]  

  • 17. [Changes in prostacyclin and thromboxane A2 in coronary circulation, and their relation to coronary hemodynamics during reperfusion after global ischemia in canine hearts].
    Nomura F
    Nihon Kyobu Geka Gakkai Zasshi; 1985 Nov; 33(11):2109-17. PubMed ID: 3912439
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory activity.
    Murakami M; Kinukawa M; Kanazawa T; Maruyama K; Miyagi M; Miyata H; Ujiie A
    J Pharmacol Exp Ther; 1996 Nov; 279(2):877-83. PubMed ID: 8930195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thromboxane synthetase inhibition reduces ventricular irritability after coronary occlusion and reperfusion.
    Austin JC; Berrizbeitia LD; Schoen FJ; Kauffman RP; Hechtman HB; Cohn LH
    Am Heart J; 1988 Mar; 115(3):505-9. PubMed ID: 3344655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term myocardial preservation: thromboxane production and coronary resistance.
    van Rijk GL; Foegh M; Ramwell PW; Goldman M; Lower RR
    J Surg Res; 1983 Nov; 35(5):417-20. PubMed ID: 6688844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.